PFIZER CEO: ‘Covid Jab Offers Limited Protection, If Any’ Against Infection

  |  
Jan 11, 2022
NEW YORK, NY – JANUARY 17: Albert Bourla, chief executive officer of Pfizer pharmaceutical company, waits to ring the closing bell at the New York Stock Exchange (NYSE) on Thursday afternoon, January 17, 2019 in New York City. The Dow Jones Industrial Average was up over 150 points at the close on Thursday, after news reports that Treasury Secretary Steven Mnuchin is floating a proposal to lift some U.S. tariffs on Chinese goods in an effort to push trade talks forward between the U.S. and China. (Photo by Drew Angerer/Getty Images)

Pfizer CEO Albert Bourla recently did an interview with CNBC in which he stated that two doses of the Covid-19 inoculation gave “very limited protection if any,” before claiming that three doses with a booster offer reasonable protection against hospitalization, but still barely protect against infection. 

“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”

CNBC also reported that data out of the United Kingdom demonstrated that two doses of Pfizer’s or Moderna’s shots, which is to say the full inoculation regimen, are only about 10% effective at preventing infection from omicron about 20 weeks after the second dose. In other words, the shot is virtually useless in regards to preventing infection less than half a year after receiving it.

“Two doses of the vaccine offers very limited protection, if any,” said Bourla during the interview. “3 doses with a booster offer reasonable protection against hospitalization and deaths.”

Bourla has claimed in the past that the Pfizer Covid-19 inoculations were 100% effective in preventing the illness.

“Excited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing #COVID19 cases in South Africa,” the Pfizer CEO wrote back in April. “100%!”

In other recent news, Bourla has announced a 4th dose of the Pfizer Covid-19 inoculation supposedly targeted at the very mild Omicron variant, promising it will be ready by this March.

“We [are] already starting manufacturing some of these quantities at risk,” Bourla said. “The hope is that we will achieve something that will have way, way better protection particularly against infections, because the protection against the hospitalizations and the severe disease — it is reasonable right now, with the current vaccines as long as you are having let’s say the third dose.”

Support Big League Politics by making a donation today. You can also donate via PayPal, Venmo or donate crypto. Your support helps us take on the powerful and report the truth that the mainstream media wants to silence. 

Our Latest Articles